---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-061439"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:42:17.217150+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated

## Summary
- Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.
- Phase 1b PIONEER trial: enrollment complete for 12mg dose cohort (n=16), 20mg cohort started.
- On track to report 12mg cohort data in early Q3 2025 and 20mg cohort data by end of 2025.
- R&D expenses fell to $13.4M from $19.8M due to losmapimod discontinuation and Sanofi reimbursement.
- Cash runway expected to fund operations into at least 2027.

## SEC filing metadata
- accession: 0000950170-25-061439
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017025061439/0000950170-25-061439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017025061439/fulc-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-061439
- JSON: https://secwatch.observer/filing/0000950170-25-061439.json
- Plain text: https://secwatch.observer/filing/0000950170-25-061439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.